MeCP2 and autism: how RNA binding and genomic binding work in Rett-like conditions
Official title: MeCP2 neurological diseases: interplay between RNA binding and MeCP2 genomic occupancy
Funded at University of Colorado · NIH-11528578 · Data updated 2026-11-12
Researchers are studying how changes in MeCP2, a gene linked to autism and Rett syndrome, interact with RNA to affect brain development.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Colorado NIH-funded |
| Lab location | 1 site (Boulder, UNITED STATES) |
| Project start | July 1, 2026 |
| Project end | June 30, 2027 |
| Funding year | 2026 |
| Award (this year) | $539,064 |
| NIH project number | 1R56NS142290-01A1 |
| Project ID | NIH-11528578 on NIH RePORTER |
Who could benefit from this research
✓Could help
Individuals with MeCP2-related conditions or autism spectrum disorders linked to MeCP2 mutations may benefit from advances in this research.
✕Less likely to help
Results may not directly translate to immediate treatments for all individuals with autism.
What this research studies
MeCP2 helps regulate gene activity in brain cells, and certain regions may bind RNA as well as DNA. This project will examine how the RNA-binding ID and AT-hook regions influence MeCP2’s control of gene expression in human cells and neurons. By introducing patient-relevant mutations, scientists will observe effects on RNA interaction and neuron differentiation to understand disease mechanisms. The study uses human stem cells to model neuronal development and will explore how disrupting these interactions could contribute to autistic features and Rett-related symptoms.
Why it matters
Potential benefit: Better understanding of MeCP2’s RNA interactions could inform therapies or diagnostics for autism and Rett syndrome.
How similar studies have gone: Previous work shows MeCP2’s DNA binding and domain functions are important, and this study extends to RNA interactions, an area with promising but emerging evidence.
Where this research is happening
-
University of Colorado
Boulder, United States Active
Researchers
- Principal investigator: Niswander, Lee a. — University of Colorado
- Study coordinator: Niswander, Lee a.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.